Early functional changes associated with alpha-synuclein proteinopathy in engineered human neural networks

Am J Physiol Cell Physiol. 2021 Jun 1;320(6):C1141-C1152. doi: 10.1152/ajpcell.00413.2020. Epub 2021 May 5.

Abstract

A patterned spread of proteinopathy represents a common characteristic of many neurodegenerative diseases. In Parkinson's disease (PD), misfolded forms of α-synuclein proteins accumulate in hallmark pathological inclusions termed Lewy bodies and Lewy neurites. Such protein aggregates seem to affect selectively vulnerable neuronal populations in the substantia nigra and to propagate within interconnected neuronal networks. Research findings suggest that these proteinopathic inclusions are present at very early time points in disease development, even before clear behavioral symptoms of dysfunction arise. In this study, we investigate the early pathophysiology developing after induced formation of such PD-related α-synuclein inclusions in a physiologically relevant in vitro setup using engineered human neural networks. We monitor the neural network activity using multielectrode arrays (MEAs) for a period of 3 wk following proteinopathy induction to identify associated changes in network function, with a special emphasis on the measure of network criticality. Self-organized criticality represents the critical point between resilience against perturbation and adaptational flexibility, which appears to be a functional trait in self-organizing neural networks, both in vitro and in vivo. We show that although developing pathology at early onset is not clearly manifest in standard measurements of network function, it may be discerned by investigating differences in network criticality states.

Keywords: Parkinson’s disease; SoC; neural networks; neurodegenerative disease; plasticity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Humans
  • Inclusion Bodies / metabolism
  • Lewy Bodies / metabolism
  • Nerve Net / metabolism*
  • Neurons / metabolism*
  • Parkinson Disease / metabolism
  • alpha-Synuclein / metabolism*

Substances

  • alpha-Synuclein